Webinar: Improve Alzheimer’s disease detection with innovative, FDA-cleared PrecivityAD2® blood biomarker testing
PrecivityAD2® testing: An innovative, noninvasive alternative for early diagnosis
This webinar explores the evolving landscape and the clinical role of emerging blood biomarker technologies in supporting timely diagnosis and patient care. There is no cost to attend.
With a focus on the newly FDA-cleared PrecivityAD2® blood test, which is offered by Mayo Clinic Laboratories in collaboration with C2N Diagnostics, the discussion will highlight how blood biomarker test results support timely diagnosis and informed clinical decision-making.
Learning objectives
Upon completion of this activity, participants should be able to:
- Describe the evolving role of blood biomarker testing in the diagnosis of Alzheimer's disease.
- Understand the clinical utility of blood biomarker tests for detecting amyloid pathology.
- Explain how blood biomarker testing can support earlier diagnosis and informed clinical decision-making.
SAVE THE DATE:
OCT. 29, 2026
Intended audience
Any neurologist, primary care physician, geriatrician, geriatric psychiatrist or psychologist, advanced practice provider, and healthcare professional involved in the evaluation and management of patients with cognitive impairment and Alzheimer’s disease.
Presenters
Chief Scientific Officer for
Mayo Clinic Laboratories
Bio
Dr. Binnicker is the chief scientific officer of Mayo Clinic Laboratories, has served as the director of the Clinical Virology and Clinical Microbiology Molecular Laboratories, and is a professor of laboratory medicine and pathology at Mayo Clinic. As chief scientific officer, Dr. Binnicker spearheads the scientific endeavors of Mayo Clinic Laboratories and leads product research, design, and development initiatives. He also works closely with leaders in Mayo Clinic's Department of Laboratory Medicine and Pathology, with other independent clinical laboratories, and with leading diagnostic manufacturers to provide advanced testing and pathology services for healthcare organizations.
Professor of Neurology at Mayo Clinic
Bio
Dr. Petersen is a neurologist who holds the Cora Kanow Professorship in Alzheimer's Disease Research at Mayo Clinic.His clinical and research interests include investigations of cognition in normal aging, mild cognitive impairment and dementia, including Alzheimer’s disease, Lewy body dementia, frontotemporal dementia, primary progressive aphasia, corticobasal degeneration, progressive supranuclear palsy, and posterior cortical atrophy.
Co-founder and CEO of C2N Diagnostics
Bio
Dr. Braunstein is co-founder and CEO of C2N Diagnostics and has led the company's growth and commercial efforts since its inception. He received his M.D. with highest distinction from Northwestern University Medical School. Subsequently, he trained in internal medicine at the Brigham and Women’s Hospital, Harvard Medical School, and was a fellow in cardiovascular medicine and a Robert Wood Johnson National Clinical Scholar at the Johns Hopkins Medical Institutions. Additionally, he completed an MBA with a management and health policy focus and maintained an assistant professorship in cardiology at Johns Hopkins University. In 2010, he was named a Distinguished Alumnus of Johns Hopkins University. Dr. Braunstein also currently serves on the Board of Advisors for the Chemistry Life Processes Department at Northwestern University.
Questions
Contact us at mcleducation@mayo.edu for more information.